PTC wins US approval of gene therapy for fatal enzyme disorder
1 day ago — PTC Therapeutics on Wednesday won Food and Drug Adminitration approval for Kebilidi, the first gene therapy cleared in the U.S. for direct administration to the brain. The treatment is designed for patients with aromatic L-amino acid decarboxylase, or AADC, deficiency, a condition that affects the way neurons transmit information to other cells.
FDA Approves First Gene Therapy for Treatment of Aromatic L …
1 day ago — Kebilidi should be administered in a medical center that specializes in pediatric stereotactic neurosurgery — a technique that uses imaging and special equipment to deliver therapies to specific ...
PTC Therapeutics Announces FDA Approval of AADC Deficiency …
1 day ago — Indication. KEBILIDI is an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency ...
PTC wins FDA approval for first brain-delivered gene therapy Kebilidi
1 day ago — England's NICE signs off on PTC Therapeutics' $3.7M gene therapy for ultra-rare disease. ... Kebilidi has already been approved in Europe, the U.K., Israel, Brazil and Taiwan as Upstaza, albeit in ...
PTC Therapeutics Wins First FDA Approval for a Gene Therapy …
1 day ago — The PTC Therapeutics gene therapy, Kebilidi, treats an enzyme deficiency that affects the body’s ability to produce dopamine, a neurotransmitter important for motor control. FDA approval for the ...
Kebilidi, a Gene Therapy for AADC Deficiency, Gets Accelerated
1 day ago — PTC Therapeutics announces FDA approval of AADC deficiency gene therapy. News release. PTC Therapeutics. November 13, 2024. ... Kebilidi. Package insert. PTC Therapeutics; 2024. Accessed November ...
PTC Therapeutics Announces FDA Approval of AADC
2 days ago — WARREN, N.J., Nov. 13, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the ...
FDA grants accelerated approval for PTC’s AADC deficiency gene …
1 day ago — Credit: Gatot Adri via Shutterstock. The US Food and Drug Administration (FDA) has granted accelerated approval for PTC Therapeutics ’ KEBILIDI, the first gene therapy in the US that is directly delivered to the brain. This therapy is designed to address the needs of children and adults with aromatic L-amino acid decarboxylase (AADC) deficiency.
US FDA approves PTC Therapeutics' gene therapy for ultra-rare …
1 day ago — The therapy, sold under the brand name Kebilidi, is a one-time treatment for children and adults with an ultra rare inherited disorder called aromatic l-amino acid decarboxylase (AADC) deficiency.
FDA approves Kebilidi as first gene therapy to treat aromatic L …
1 day ago — The first gene therapy for for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency for adults and pediatric patients, eladocagene exuparvovec-tneq (Kebilidi; PTC Therapeutics), has been approved by the FDA according to an announcement from the federal agency. 1 AADC deficiency is a rare genetic disorder that affects production of neurotransmitters that are chemical ...
- Some results have been removed